[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

组别	例数	NLR	WBC（×10⁹/L）	hs-CRP（mg/L）	NEUT#（×10⁹/L）	NEUT%（%）
感染组	120	5.62（4.07~7.72）^*#	28.59±7.45^*#	2.31（0.53~6.03）^*#	22.53±6.39^*#	78.58±6.40^*#
黄疸组	60	3.18（2.58~3.53）	24.09±4.62	0.72（0.50~2.00）	16.70±3.64	69.18±5.15
健康组	60	3.15（2.71~3.55）	24.74±3.52	0.87（0.50~2.48）	17.12±2.74	69.18±4.83

组别	例数	NLR	WBC（×10⁹/L）	hs-CRP（mg/L）	NEUT#（×10⁹/L）	NEUT%（%）
感染组	120	5.62（4.07~7.72）^*#	28.59±7.45^*#	2.31（0.53~6.03）^*#	22.53±6.39^*#	78.58±6.40^*#
黄疸组	60	3.18（2.58~3.53）	24.09±4.62	0.72（0.50~2.00）	16.70±3.64	69.18±5.15
健康组	60	3.15（2.71~3.55）	24.74±3.52	0.87（0.50~2.48）	17.12±2.74	69.18±4.83

项目	AUC	最佳临界值	临床界值	敏感性（%）	特异性（%）	阳性预测值（%）	阴性预测值（%）	准确率（%）	建议用途
NLR	0.903	4		75.8	99.2	98.9	88.4	87.5	诊断
hs-CRP	0.653	3 mg/L		42.5	83.3	71.8	59.2	62.9	诊断
			8 mg/L	18.3	97.5	88.0	54.1	57.9	筛查
WBC计数	0.681	30×10⁹/L		44.2	0.9	81.5	61.7	67.1	诊断
			20×10⁹/L	90.0	15.8	51.7	61.3	52.9	筛查
NEUT%	0.876	75%	75%	71.7	90.0	87.8	90.0	80.8	诊断

项目	AUC	最佳临界值	临床界值	敏感性（%）	特异性（%）	阳性预测值（%）	阴性预测值（%）	准确率（%）	建议用途
NLR	0.903	4		75.8	99.2	98.9	88.4	87.5	诊断
hs-CRP	0.653	3 mg/L		42.5	83.3	71.8	59.2	62.9	诊断
			8 mg/L	18.3	97.5	88.0	54.1	57.9	筛查
WBC计数	0.681	30×10⁹/L		44.2	0.9	81.5	61.7	67.1	诊断
			20×10⁹/L	90.0	15.8	51.7	61.3	52.9	筛查
NEUT%	0.876	75%	75%	71.7	90.0	87.8	90.0	80.8	诊断

RichHTML

PDF (PC)

[1]	邵肖梅,叶鸿瑁,丘小汕. 实用儿科学[M]. 4版. 北京:人民卫生出版社,2011:588-589.
[2]	肖萍. 超敏C-反应蛋白联合白细胞检测在新生儿细菌感染性疾病中的应用[J]. 检验医学与临床,2012,9(12):1441-1442.
[3]	欧丽荣,陈锐芳. CRP和WBC联合检测在新生儿急性感染性疾病中的诊断意义[J]. 国际检验医学杂志,2016,37(8):1150-1151.
[4]	冯广满,蒋旺珍,罗配红,等. 新生儿感染早期诊断指标PCT与hs-CRP相关性的研究[J]. 现代诊断与治疗,2015,26(18):4263-4264.
[5]	WINDGASSEN E B,FUNTOWICZ L,LUNSFORD T N,et al.C-reactive protein and high-sensitivity C-reactive protein:an update for clinicians[J]. Postgrad Med,2011,123(1):114-119.